Boehringer Ingelheim and Lilly announce an academic collaboration with University of Oxford

Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) have announced an academic collaboration with the University of Oxford. EMPA-KIDNEY will investigate the effects of empagliflozin on the progression of kidney disease and the occurrence of cardiovascular death, in people with established chronic kidney disease with and without diabetes.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news